Effect of Cetuximab and EGFR Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type EGFR and Use of KRAS as a Possible Biomarker for Treatment Responsiveness

DOI: 10.33160/yam.2019.03.012

Keywords: cetuximab, EGFR siRNA, KRAS, non-small cell lung cancer

Full-Text   Cite this paper   Add to My Lib

Abstract:

pj.ca.u-irottot.dem@imukih

Full-Text